$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000162828022005771 Filed on March 11, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$0.00	$0.00	$5.000M
YoY Change	-100.0%	-100.0%	27677.78%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.551M	$10.02M	$2.080M
YoY Change	22.64%	13.76%	-11.86%
% of Gross Profit
Research & Development	$4.371M	$17.79M	$3.850M
YoY Change	13.53%	15.94%	95.43%
% of Gross Profit
Depreciation & Amortization	$41.00K	$459.0K	$110.0K
YoY Change	-62.73%	-8.2%	-15.38%
% of Gross Profit
Operating Expenses	$6.960M	$27.82M	$6.028M
YoY Change	15.46%	15.13%	35.37%
Operating Profit		-$27.82M
YoY Change		96.51%
Interest Expense	-$173.0K	$855.0K	-$290.0K
YoY Change	-40.34%	-52.71%	-36.96%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$7.133M	-$27.81M	-$1.320M
YoY Change	440.38%	76.78%	-73.01%
Income Tax	$0.00	$1.000K	$10.00K
% Of Pretax Income
Net Earnings	-$7.133M	-$27.81M	-$1.322M
YoY Change	439.56%	76.78%	-72.98%
Net Earnings / Revenue			-26.44%
Basic Earnings Per Share		-$0.32
Diluted Earnings Per Share	-$665.8K	-$0.32	-$27.60K
COMMON SHARES
Basic Shares Outstanding	87.05M shares	85.70M shares	39.16M shares
Diluted Shares Outstanding		85.70M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.38M	$60.38M	$31.10M
YoY Change	94.16%	94.16%	-8.8%
Cash & Equivalents	$60.38M	$60.38M	$31.09M
Short-Term Investments
Other Short-Term Assets	$1.780M	$4.852M	$1.826M
YoY Change	-2.52%	-4.86%	49.55%
Inventory
Prepaid Expenses	$3.010M		$3.314M
Receivables	$0.00	$0.00	$500.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$65.24M	$65.24M	$36.73M
YoY Change	77.61%	77.75%	-9.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$281.0K	$2.845M	$472.0K
YoY Change	-40.47%	469.0%	-48.75%
Goodwill
YoY Change
Intangibles	$83.00K		$125.0K
YoY Change	-33.6%		-53.01%
Long-Term Investments
YoY Change
Other Assets	$291.0K	$291.0K	$24.00K
YoY Change	1112.5%	-3.0%	-95.07%
Total Long-Term Assets	$3.219M	$3.219M	$874.0K
YoY Change	268.31%	257.67%	-47.79%
TOTAL ASSETS
Total Short-Term Assets	$65.24M	$65.24M	$36.73M
Total Long-Term Assets	$3.219M	$3.219M	$874.0K
Total Assets	$68.45M	$68.45M	$37.60M
YoY Change	82.04%	82.06%	-10.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$285.0K	$285.0K	$535.0K
YoY Change	-46.73%	-43.0%	-59.5%
Accrued Expenses	$821.0K	$3.647M	$581.0K
YoY Change	41.31%	7.26%	-24.55%
Deferred Revenue			$0.00
YoY Change			-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$4.700M
YoY Change	-100.0%	-100.0%	-68.46%
Total Short-Term Liabilities	$5.227M	$5.227M	$11.58M
YoY Change	-54.85%	-54.94%	-46.39%
LONG-TERM LIABILITIES
Long-Term Debt	$4.673M	$4.673M	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$1.179M	$3.596M	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$5.852M	$8.269M	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.227M	$5.227M	$11.58M
Total Long-Term Liabilities	$5.852M	$8.269M	$0.00
Total Liabilities	$13.50M	$13.50M	$11.58M
YoY Change	16.57%	16.34%	-47.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$454.9M		-$427.0M
YoY Change	6.51%		3.82%
Common Stock	$509.8M		$453.1M
YoY Change	12.52%		5.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$54.96M	$54.96M	$26.03M
YoY Change
Total Liabilities & Shareholders Equity	$68.45M	$68.45M	$37.60M
YoY Change	82.04%	82.06%	-10.64%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$7.133M	-$27.81M	-$1.322M
YoY Change	439.56%	76.78%	-72.98%
Depreciation, Depletion And Amortization	$41.00K	$459.0K	$110.0K
YoY Change	-62.73%	-8.2%	-15.38%
Cash From Operating Activities	-$7.831M	-$24.13M	$3.190M
YoY Change	-345.49%	92.47%	-164.06%
INVESTING ACTIVITIES
Capital Expenditures	-$41.00K	$251.0K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$41.00K	-$251.0K	$0.00
YoY Change		2181.82%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$21.43M
YoY Change		2139.39%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	32.41M	$53.74M	10.05M
YoY Change	222.46%	464.88%	-59.0%
NET CHANGE
Cash From Operating Activities	-7.831M	-$24.13M	3.190M
Cash From Investing Activities	-41.00K	-$251.0K	0.000
Cash From Financing Activities	32.41M	$53.74M	10.05M
Net Change In Cash	24.54M	$29.36M	13.24M
YoY Change	85.31%	-1067.63%	-32.0%
FREE CASH FLOW
Cash From Operating Activities	-$7.831M	-$24.13M	$3.190M
Capital Expenditures	-$41.00K	$251.0K	$0.00
Free Cash Flow	-$7.790M	-$24.38M	$3.190M
YoY Change	-344.2%	94.47%	-164.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Local Phone Number LocalPhoneNumber	202-6300
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
CY2020	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://www.regulusrx.com/20211231#RevenueUnderCollaborationsMember
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://www.regulusrx.com/20211231#RevenueUnderCollaborationsMember
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-35670
CY2021	dei	Entity Registrant Name EntityRegistrantName	Regulus Therapeutics Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-4738379
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	4224 Campus Point Court, Suite 210
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2021	dei	City Area Code CityAreaCode	858
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Trading Symbol TradingSymbol	RGLS
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	67800000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	145971184	shares
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60383000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31087000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	62000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	0	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	503000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3010000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3314000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1780000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1826000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	65235000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	36730000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	281000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	472000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	83000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	125000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2564000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	253000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	291000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24000	USD
CY2021Q4	us-gaap	Assets Assets	68454000	USD
CY2020Q4	us-gaap	Assets Assets	37604000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	285000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	535000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	821000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	581000	USD
CY2021Q4	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	810000	USD
CY2020Q4	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1097000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2016000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1743000	USD
CY2021Q4	us-gaap	Debt Current DebtCurrent	0	USD
CY2020Q4	us-gaap	Debt Current DebtCurrent	4652000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1295000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2970000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5227000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11578000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2417000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4673000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1179000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2021Q4	us-gaap	Liabilities Liabilities	13496000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	11578000	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	145971184	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	145971184	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67432712	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67432712	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	146000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	67000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	509660000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	453002000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-454853000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-427045000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	54958000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	26026000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68454000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37604000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10006000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10006000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17794000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15347000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10022000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8814000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	27816000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	24161000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-27816000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-14155000	USD
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	864000	USD
CY2020	us-gaap	Interest And Other Income InterestAndOtherIncome	233000	USD
CY2021	us-gaap	Interest Expense InterestExpense	855000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1808000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27807000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15730000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27808000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15730000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85704535	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85704535	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34977378	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34977378	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20015000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	USD
CY2020	rgls	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	692000	USD
CY2020	rgls	Stock Issued During Period Shares Preferred Stock Warrants From Private Placement Netof Offering Costs Value StockIssuedDuringPeriodSharesPreferredStockWarrantsFromPrivatePlacementNetofOfferingCostsValue	18166000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2614000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	262000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15730000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	26026000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26000	USD
CY2021	rgls	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	832000	USD
CY2021	rgls	Stock Issued During Period Shares Preferred Stock Warrants From Private Placement Netof Offering Costs Value StockIssuedDuringPeriodSharesPreferredStockWarrantsFromPrivatePlacementNetofOfferingCostsValue	32360000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2923000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20592000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27808000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	54958000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27808000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15730000	USD
CY2020	rgls	Gain Loss On Loan Forgiveness GainLossOnLoanForgiveness	0	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2923000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-786000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	240000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-188000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	459000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	467000	USD
CY2021	rgls	Gain Loss On Loan Forgiveness GainLossOnLoanForgiveness	662000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2614000	USD
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	46000	USD
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	154000	USD
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-503000	USD
CY2020	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-638000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-304000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-610000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	221000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	605000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-250000	USD
CY2021	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-287000	USD
CY2020	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	949000	USD
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	273000	USD
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	66000	USD
CY2021	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	279000	USD
CY2020	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	-150000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	73000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-569000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24128000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12536000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	251000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-251000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11000	USD
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	32360000	USD
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	18166000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21431000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	957000	USD
CY2021	rgls	Proceeds From Federal Program ProceedsFromFederalProgram	0	USD
CY2020	rgls	Proceeds From Federal Program ProceedsFromFederalProgram	662000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000	USD
CY2021	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	80000	USD
CY2020	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	277000	USD
CY2021	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
CY2020	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	10000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53737000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9513000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29358000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3034000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31087000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34121000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60445000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31087000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60383000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31087000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	62000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60445000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31087000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	729000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1356000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	USD
CY2021	rgls	Paycheck Protection Program Loan Forgiveness PaycheckProtectionProgramLoanForgiveness	662000	USD
CY2020	rgls	Paycheck Protection Program Loan Forgiveness PaycheckProtectionProgramLoanForgiveness	0	USD
CY2021	rgls	Noncash Unsettled Sales Of Common Stock Through Atm NoncashUnsettledSalesOfCommonStockThroughATM	0	USD
CY2020	rgls	Noncash Unsettled Sales Of Common Stock Through Atm NoncashUnsettledSalesOfCommonStockThroughATM	392000	USD
CY2021	rgls	Financingfrom Sale Proceeds Debt Agreement Revenues FinancingfromSaleProceedsDebtAgreementRevenues	538000000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60400000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesOur financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Additionally, the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty.
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We have not experienced any material losses in such accounts and believe we are not exposed to significant risk. We maintain our cash equivalents with two highly accredited financial institutions. We have invested our excess cash primarily in money market funds. Additionally, we adhere to established guidelines regarding approved investments and maturities of investments, which are designed to preserve their principal value and maintain liquidity.</span></div>
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	92556717	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	70751812	shares
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	USD
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	57905000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	26901000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	5000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4595000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5331000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4314000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4859000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	281000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	472000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	100000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	100000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	100000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	100000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	100000	USD
CY2021	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P11Y9M18D
	rgls	Number Of Amendments NumberOfAmendments	8	amendment
CY2020Q2	rgls	Forgiveness Amount Threshold ForgivenessAmountThreshold	500000	USD
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	145971184	shares
CY2021Q4	rgls	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
CY2020Q1	rgls	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized Period For Yearly Increase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease	P10Y
CY2019Q2	rgls	Number Of Closings NumberOfClosings	2	closing
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8661000	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	130872000	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2923000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2614000	USD
CY2021	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	11619	shares
CY2021	rgls	Defined Contribution Minimum Age Requirement Of Eligible Employees DefinedContributionMinimumAgeRequirementOfEligibleEmployees	P18Y
CY2021	rgls	Defined Contribution Plan Employee Contributions Percentageof Eligible Compensation DefinedContributionPlanEmployeeContributionsPercentageofEligibleCompensation	0.50
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.50
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.06
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-13000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-12000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	12000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	12000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5840000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3309000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-927000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1180000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1216000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6659000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2606000	USD
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	80000	USD
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-14000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	243000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1644000	USD
CY2021	rgls	Effective Income Tax Rate Reconciliation Reservefor Uncertain Tax Positions Amount EffectiveIncomeTaxRateReconciliationReserveforUncertainTaxPositionsAmount	176000	USD
CY2020	rgls	Effective Income Tax Rate Reconciliation Reservefor Uncertain Tax Positions Amount EffectiveIncomeTaxRateReconciliationReserveforUncertainTaxPositionsAmount	1179000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-138000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	37000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17000000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	282000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	124828000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	87877000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	82747000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	35344000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	34337000	USD
CY2021Q4	rgls	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	607000	USD
CY2020Q4	rgls	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	715000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	587000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	283000	USD
CY2021Q4	rgls	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	631000	USD
CY2020Q4	rgls	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	88000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	564000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	281000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	125610000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	118451000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	782000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	118169000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	118169000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	124828000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	124800000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17939000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16573000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1174000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	188000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1367000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16953000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17939000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	13700000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2564000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	253000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	288000	USD
CY2021Q4	rgls	Lease Right Of Use Asset LeaseRightOfUseAsset	2564000	USD
CY2020Q4	rgls	Lease Right Of Use Asset LeaseRightOfUseAsset	541000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	589000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	417000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	56000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2417000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2021Q4	rgls	Lease Liabilities LeaseLiabilities	3006000	USD
CY2020Q4	rgls	Lease Liabilities LeaseLiabilities	473000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	746000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	278000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	29000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	178000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10000	USD
CY2021	us-gaap	Lease Cost LeaseCost	30000	USD
CY2020	us-gaap	Lease Cost LeaseCost	188000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	468000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	429000	USD
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1000	USD
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	10000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	80000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	277000	USD
CY2021	rgls	Operatingand Finance Lease Payments OperatingandFinanceLeasePayments	549000	USD
CY2020	rgls	Operatingand Finance Lease Payments OperatingandFinanceLeasePayments	716000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3006000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.109
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.049
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	754000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	776000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	800000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	824000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	277000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3431000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	425000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3006000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	589000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2417000	USD
CY2021	dei	Auditor Firm AuditorFirmId	42

Files In Submission

Name	View Source	Status
0001628280-22-005771-index-headers.html	Edgar Link	pending
0001628280-22-005771-index.html	Edgar Link	pending
0001628280-22-005771.txt	Edgar Link	pending
0001628280-22-005771-xbrl.zip	Edgar Link	pending
a2021ex-311xcertofprincipa.htm	Edgar Link	pending
a2021ex-312xcertofprincipa.htm	Edgar Link	pending
a2021ex-321xcertpursuantto.htm	Edgar Link	pending
ex1014-hagansalaryupdate.htm	Edgar Link	pending
ex1015-akersalaryupdate.htm	Edgar Link	pending
ex1016-calsadasalaryupdate.htm	Edgar Link	pending
ex1017-dryginsalaryupdate.htm	Edgar Link	pending
ex1037-10thamendmentoxfo.htm	Edgar Link	pending
ex1037-10thamendmentoxfo001.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo002.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo003.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo004.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo005.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo006.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo007.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo008.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo009.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo010.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo011.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo012.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo013.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo014.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo015.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo016.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo017.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo018.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo019.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo020.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo021.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo022.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo023.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo024.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo025.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo026.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo027.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo028.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo029.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo030.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo031.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo032.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo033.jpg	Edgar Link	pending
ex1037-10thamendmentoxfo034.jpg	Edgar Link	pending
ex231-10xkeyconsent.htm	Edgar Link	pending
ex43-descriptionofcommonst.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20211231.htm	Edgar Link	pending
rgls-20211231.xsd	Edgar Link	pending
rgls-20211231_cal.xml	Edgar Link	unprocessable
rgls-20211231_def.xml	Edgar Link	unprocessable
rgls-20211231_g1.jpg	Edgar Link	pending
rgls-20211231_htm.xml	Edgar Link	completed
rgls-20211231_lab.xml	Edgar Link	unprocessable
rgls-20211231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2021 Q4 Form 10-K Financial Statement

#000162828022005771 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2021 Q4 Form 10-K Financial Statement

#000162828022005771 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls